论文部分内容阅读
目的:观察卡托普利合厄贝沙坦治疗高血压肾损害的临床疗效。方法:将42例患者随机分为两组,治疗组26例,对照组16例,对照组口服厄贝沙坦治疗,治疗组采用卡托普利合厄贝沙坦治疗,疗程为6周,观测血压(包括舒张压及收缩压)、尿β2-MG的指标变化情况及临床疗效。结果:两组患者血压均有所下降,尿β2-MG值减少,组间比较有统计学意义(P<0.05)。治疗组整体疗效优于对照组(P<0.05)。结论:卡托普利合厄贝沙坦治疗高血压肾损害疗效满意。
Objective: To observe the curative effect of captopril and irbesartan on hypertensive renal damage. Methods: Forty-two patients were randomly divided into two groups: treatment group (26 cases), control group (16 cases), control group (oral irbesartan treatment), treatment group (captopril or irbesartan) Observed blood pressure (including diastolic and systolic blood pressure), urinary β2-MG index changes and clinical efficacy. Results: The blood pressure of both groups decreased and the level of urinary β2-MG decreased. There was a significant difference between the two groups (P <0.05). The overall efficacy of the treatment group was better than that of the control group (P <0.05). Conclusion: Captopril and irbesartan are effective in treating hypertensive renal failure.